Clinical Trial Update: Study of TVB-2640 in Subjects With Nonalcoholic Steatohepatitis (NASH) [Phase 2]

View source ↗

Summary

Sagimet Biosciences completed a Phase 2 study of TVB-2640 in nonalcoholic steatohepatitis (NASH) with results posted in May 2025.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nonalcoholic Fatty Liver Disease
• Nonalcoholic Steatohepatitis

Drugs mentioned

• TVB-2640

Snippet

Sponsor: Sagimet Biosciences Inc. | Conditions: Metabolic Dysfunction-assocated Steatohepatitis/ Nonalcoholic Fatty Liver Disease | Phase 2 | Status: COMPLETED | Results posted: 2025-05-09